LLY - Lilly(Eli) & Co
(NaN%)
SNP 500
Sell
Gross Profit was Negative
54%
based on last 5 year data.
Income Statement is MODERATE
Revenue Growth is 450426999999900.0%
Operating Income turning Positive
Net Income Growth is 102.08%
Earnings Per Share (EPS) Growth is 101.9%
Net Margin is 23.51%
Balance Sheet is MODERATE
Current Asset to Current Liability Ratio is 1.15
Debt Ratio is 0.82
Current Debt to Net Income Ratio is 0.48
Total Debt to Total Assets Ratio is 0.44
Cash Flow is STRONG
Cash from Operations Growth is 107.96%
Capital Expenditure is Low
Net Increase in Cash is Positive
Long Term Score Trend is NEUTRAL
Investment Risk is High
based on last 4 quarter data.
Better viewed in landscape mode.
Unless specified, all values are in USD Millions. Data extracted from SEC Filing and are subject to processing and input errors.
Lilly(Eli) & Co (LLY) - www.lilly.com
Lilly is a global health care leader that unites caring with discovery to create medicines that make life better for people around the world. It was founded more than a century ago by a man committed to creating high-quality medicines that meet real needs, and today it remains true to that mission in all its work. Across the globe, Lilly employees work to discover and bring life-changing medicines to those who need them, improve the understanding and management of disease, and give back to communities through philanthropy and volunteerism.Exchange - NEW YORK STOCK EXCHANGE INC.
Industry - Pharmaceutical Preparation Manufacturing
Sector - Manufacturing
CEO - David Ricks
Employees - 2,020
Disclaimer - Investment in securities involves substantial risk and could result in significant loss. It is not suitable for every investor. Before acting on information on this website, you should consider whether it is suitable for your particular circumstances and strongly consider seeking advice from your own financial or investment adviser. We may own some of the securities mentioned in this website.
Know the Stock © 2025 and future.
Know the Stock © 2025 and future.